Becton, Dickinson and Company (NYSE:BDX) Price Target Lowered to $157.00 at Wells Fargo & Company

Becton, Dickinson and Company (NYSE:BDX) had its price target reduced by Wells Fargo & Company from $184.00 to $157.00 in a research report sent to investors on Tuesday,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the medical instruments supplier’s stock.

Other equities research analysts have also issued reports about the stock. Citigroup started coverage on shares of Becton, Dickinson and Company in a report on Tuesday, February 3rd. They set a “buy” rating and a $233.00 price target for the company. Bank of America increased their target price on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a report on Monday, January 5th. Jefferies Financial Group upped their price target on Becton, Dickinson and Company from $215.00 to $220.00 and gave the company a “buy” rating in a research report on Wednesday, December 10th. Barclays initiated coverage on Becton, Dickinson and Company in a research report on Tuesday. They issued an “overweight” rating and a $202.00 price objective on the stock. Finally, Morgan Stanley upped their target price on Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Five analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Becton, Dickinson and Company has an average rating of “Hold” and an average price target of $196.00.

Becton, Dickinson and Company Stock Down 17.3%

Shares of NYSE:BDX opened at $171.55 on Tuesday. The stock has a market capitalization of $48.88 billion, a P/E ratio of 27.99, a price-to-earnings-growth ratio of 2.72 and a beta of 0.25. The stock’s 50-day moving average price is $199.76 and its 200-day moving average price is $192.43. The company has a current ratio of 1.05, a quick ratio of 0.64 and a debt-to-equity ratio of 0.67. Becton, Dickinson and Company has a 12-month low of $162.29 and a 12-month high of $235.34.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating the consensus estimate of $2.81 by $0.10. The company had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.15 billion. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.Becton, Dickinson and Company’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same period in the prior year, the business posted $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, equities analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 68.52%.

Becton, Dickinson and Company announced that its board has approved a stock repurchase program on Tuesday, January 27th that allows the company to buyback $10.00 million in outstanding shares. This buyback authorization allows the medical instruments supplier to buy up to 0% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its stock is undervalued.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the transaction, the executive vice president directly owned 12,095 shares in the company, valued at approximately $2,509,228.70. This trade represents a 11.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 2,463 shares of company stock worth $501,530 over the last ninety days. 0.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Activest Wealth Management raised its position in shares of Becton, Dickinson and Company by 285.3% in the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 97 shares during the last quarter. Imprint Wealth LLC purchased a new position in Becton, Dickinson and Company in the third quarter worth about $25,000. SOA Wealth Advisors LLC. lifted its stake in shares of Becton, Dickinson and Company by 256.8% in the third quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 95 shares in the last quarter. Steph & Co. grew its holdings in shares of Becton, Dickinson and Company by 95.6% during the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 65 shares during the last quarter. Finally, Bell Investment Advisors Inc increased its position in shares of Becton, Dickinson and Company by 474.1% during the second quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 128 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company News Roundup

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Q1 results beat consensus — adjusted EPS $2.91 vs. $2.81 expected and revenue $5.25B vs. $5.15B, showing organic revenue stability and margin improvement that would normally support the stock. BD Reports First Quarter Fiscal 2026 Financial Results
• Positive Sentiment: Company announced up to $1.6B in cash tender offers to repurchase certain outstanding debt — a signal of active balance‑sheet management that can reduce leverage and interest burden. Tender Offers for Outstanding Debt Securities
• Positive Sentiment: Barclays initiated coverage with an Overweight and $202 PT — a notable constructive analyst call amid mixed revisions. Barclays Overweight Initiation
• Neutral Sentiment: Spin-off/combination with Waters completed — a structural change that reduces BD’s scale and alters its earnings base; investors are re‑valuing the “New BD” through guidance and cash deployment plans. Spin-off/Combination Announcement
• Neutral Sentiment: Insiders placed bullish option bets (reported) — a small positive signal of insider confidence but not large enough to move fundamentals alone. Insider Option Activity
• Negative Sentiment: Company cut FY26 adjusted EPS guidance to $12.35–$12.65, well below consensus (~$14.8) — the guidance reset (reflecting the divestiture) is the primary negative driver pushing the stock lower as investors adjust earnings models. Profit Forecast Cut
• Negative Sentiment: Multiple broker price‑target cuts and rating adjustments (JPMorgan, Wells Fargo, Jefferies, RBC and others) compress sentiment — several firms lowered PTs or shifted to neutral/equal‑weight, increasing selling pressure. Analyst Price Target Moves
• Negative Sentiment: Company flagged a reduced profit outlook tied to the sale/combination of its biosciences & diagnostics unit — the near‑term EPS hit and uncertainty around cash deployment timing weigh on valuation. Sale‑Related Profit Outlook

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.